CD163 and neoplasm: In comparison to ARID1A -proficient patients, patients with ARID1A deficiency exhibited a significant increase in the infiltration levels of CD8 + cells, CD163 + cells and FOXP3 + cells within the tumor tissue (Fig. 2b-d).